Silk Road Medical Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	1,063	989.48	823.3	739.33
Revenue Growth (YoY)	17.57%	20.18%	11.36%	-
Cost of Revenue	483.79	448.64	404.56	378
Gross Profit	578.87	540.84	418.75	361.33
Selling, General & Admin	234.64	222.88	275.79	259.49
Research & Development	114.24	108.57	-	-
Operating Expenses	349.03	331.45	275.79	259.82
Operating Income	229.84	209.4	142.96	101.5
Interest Expense	-2.61	-3.71	-6.6	-7.69
Interest & Investment Income	9.33	9.27	7.34	6.54
Currency Exchange Gain (Loss)	-	-	-3.16	10.08
Other Non Operating Income (Expenses)	-14.6	21.64	6.58	5.27
EBT Excluding Unusual Items	221.96	236.59	147.12	115.7
Gain (Loss) on Sale of Assets	-	-	-0.06	-
Pretax Income	221.96	236.59	147.07	115.7
Income Tax Expense	41.47	66.47	33.8	23.18
Net Income	180.49	170.13	113.27	92.52
Net Income to Common	180.49	170.13	113.27	92.52
Net Income Growth	26.08%	50.19%	22.43%	-
Shares Outstanding (Basic)	32	31	31	31
Shares Outstanding (Diluted)	32	32	31	31
Shares Change (YoY)	1.08%	0.02%	0.02%	-
EPS (Basic)	5.70	5.43	3.61	2.96
EPS (Diluted)	5.68	5.40	3.60	2.94
EPS Growth	24.80%	50.08%	22.33%	-
Free Cash Flow	-268.32	-40.62	-113.36	-29.54
Free Cash Flow Per Share	-8.44	-1.29	-3.60	-0.94
Dividend Per Share	-	3.500	1.471	1.961
Dividend Growth	-	138.00%	-25.00%	-
Gross Margin	54.47%	54.66%	50.86%	48.87%
Operating Margin	21.63%	21.16%	17.36%	13.73%
Profit Margin	16.98%	17.19%	13.76%	12.51%
Free Cash Flow Margin	-25.25%	-4.11%	-13.77%	-4.00%
EBITDA	302.48	285.44	215.04	173.4
EBITDA Margin	28.46%	28.85%	26.12%	23.45%
D&A For EBITDA	72.64	76.04	72.08	71.9
EBIT	229.84	209.4	142.96	101.5
EBIT Margin	21.63%	21.16%	17.36%	13.73%
Effective Tax Rate	18.68%	28.09%	22.98%	20.03%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.